Search research articles
Contact Us
Filters
Showing results (441-450 of 869) with videos related to
Page
of 87
Sort By:
Leukemia & Lymphoma
|
February 1, 2012
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma
Jeffrey L Wolf, David Siegel, Hartmut Goldschmidt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 17, 2009
Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia
Hai T Ngo, Abdel Kareem Azab, Mena Farag, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2005
Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia
Steven P Treon, Mark Hansen, Andrew R Branagan, et al.
Cancer Research
|
December 3, 2004
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma
Laurence Catley, Yu-Tzu Tai, Reshma Shringarpure, et al.
Cancer Research
|
February 20, 2007
Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma
Klaus Podar, Marc S Raab, Giovanni Tonon, et al.
Blood Cancer Discovery
|
June 28, 2021
Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcare
Nicole Gormley, Lola Fashoyin-Aje, Trevan Locke, et al.
Molecular Cancer Therapeutics
|
June 19, 2007
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells
Tanyel Kiziltepe, Teru Hideshima, Laurence Catley, et al.
British Journal of Haematology
|
September 12, 2008
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma
Sundar Jagannath, Bart Barlogie, James R Berenson, et al.
Cells
|
November 30, 2019
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
Thomas G Martin, Kathryn Corzo, Marielle Chiron, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 23, 2011
Significant biological role of sp1 transactivation in multiple myeloma
Mariateresa Fulciniti, Samir Amin, Puru Nanjappa, et al.
Page
of 87
Search research articles
Search
Showing results (441-450 of 869) with videos related to
Sort By:
Page
of 87
Leukemia & Lymphoma
|
February 1, 2012
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma
Jeffrey L Wolf, David Siegel, Hartmut Goldschmidt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 17, 2009
Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia
Hai T Ngo, Abdel Kareem Azab, Mena Farag, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2005
Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia
Steven P Treon, Mark Hansen, Andrew R Branagan, et al.
Cancer Research
|
December 3, 2004
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma
Laurence Catley, Yu-Tzu Tai, Reshma Shringarpure, et al.
Cancer Research
|
February 20, 2007
Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma
Klaus Podar, Marc S Raab, Giovanni Tonon, et al.
Blood Cancer Discovery
|
June 28, 2021
Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcare
Nicole Gormley, Lola Fashoyin-Aje, Trevan Locke, et al.
Molecular Cancer Therapeutics
|
June 19, 2007
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells
Tanyel Kiziltepe, Teru Hideshima, Laurence Catley, et al.
British Journal of Haematology
|
September 12, 2008
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma
Sundar Jagannath, Bart Barlogie, James R Berenson, et al.
Cells
|
November 30, 2019
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
Thomas G Martin, Kathryn Corzo, Marielle Chiron, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 23, 2011
Significant biological role of sp1 transactivation in multiple myeloma
Mariateresa Fulciniti, Samir Amin, Puru Nanjappa, et al.
Page
of 87